Skip to content Skip to footer

Argentina announces plans to broaden medical cannabis schemes

Argentina announces plans to broaden medical cannabis schemes
Share this story
Share on twitter
Share on linkedin
Share on email

Eoin Keenan


 

Last week the Argentinian Minister of Health announced plans to broaden the scope of its medical cannabis programme, three years on from establishing a regulatory framework for the medical and scientific use of cannabis.

The draft regulations have not been published in the official gazette yet but were presented by the minister in a meeting with key stakeholders. The government is listening to demands from patients and advocacy groups, in order to allow patients to home-grow medical cannabis and share crops among multiple patients.

Most importantly, the list of allowed indications of medical cannabis will be expanded to include all patients which could benefit from cannabis treatment and the number of specialists registered to prescribe cannabis will also be increased.

In practice, this will drastically increase accessibility and has the potential to set the stage for the sustained growth in patient penetration as observed in other nascent markets like Germany or Australia, where over two-thirds of the prescriptions are for chronic pain.

 

 

Three pathways to the supply of medical cannabis are proposed:

  • Special importation, as had been occurring with CBD since the 2017 law was approved. On top of the import of finished products, the Minister announced that importation of raw materials to be further compounded in a magistral pharmacy, will also be allowed, aligning the Argentinian model with many European schemes, like Germany.
  • Allowing self-cultivation of medical cannabis at home under authorisation for patients included in a special registry. Collective growing by associations will also be allowed.
  • State-controlled production of cannabis oil, although the details of this scheme are still unclear.

For more in-depth information, consumer data and strategic support, contact the Prohibition Partners consultancy team at info@prohibitionpartners.com or download one of our industry-leading reports.

Recent posts
May 19, 2022
Who Are Europe’s Medical Cannabis Patients?
May 5, 2022
Europe’s Pilot Trials Are a Tentative Step Towards Legal Medical Cannabis
April 28, 2022
The First Sales of Legal Adult-Use Cannabis in Europe Are Due in 2022
April 14, 2022
One Step Forward for CBD in the UK, but Questions Remain at Home and Abroad

Catch up on our newest articles that you might have missed

Untitled design (11)
May 19, 2022
Who Are Europe’s Medical Cannabis Patients?
The relatively close integration of medical cannabis into the European healthcare systems has contributed to a patient population and purchasing...
il-vagabiondo-Q7QCj-9-q3I-unsplash
May 5, 2022
Europe’s Pilot Trials Are a Tentative Step Towards Legal Medical Cannabis
Underlining the cautious approach Europe is taking to the liberalisation of medical cannabis are the pilot trial access schemes for...
vincent-ghilione-z54zUmYA9f8-unsplash
April 28, 2022
The First Sales of Legal Adult-Use Cannabis in Europe Are Due in 2022
Last week the first pilot project trial for the legalised sales of adult-use cannabis in Basel, Switzerland was approved by...
thomas-kelley--8iE9ykf3Us-unsplash
April 14, 2022
One Step Forward for CBD in the UK, but Questions Remain at Home and Abroad
The recent publishing of the list of CBD products with a valid Novel Foods application by the UK’s Food Safety...